Relmada Therapeutics (RLMD) Projected to Post Earnings on Thursday

Relmada Therapeutics (NASDAQ:RLMD) is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Relmada Therapeutics to post earnings of ($0.21) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Relmada Therapeutics (NASDAQ:RLMD) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, analysts expect Relmada Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Relmada Therapeutics Stock Down 1.7%

NASDAQ RLMD opened at $5.14 on Thursday. The company has a market capitalization of $539.13 million, a P/E ratio of -4.72 and a beta of 0.41. Relmada Therapeutics has a 12-month low of $0.55 and a 12-month high of $8.00. The firm has a 50-day moving average price of $6.31 and a two-hundred day moving average price of $5.88.

Institutional Trading of Relmada Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. acquired a new position in Relmada Therapeutics during the first quarter valued at approximately $33,000. XTX Topco Ltd bought a new stake in shares of Relmada Therapeutics during the 2nd quarter worth $28,000. Marshall Wace LLP bought a new stake in shares of Relmada Therapeutics during the 2nd quarter worth $93,000. Jane Street Group LLC acquired a new stake in Relmada Therapeutics in the second quarter valued at about $69,000. Finally, LMR Partners LLP acquired a new stake in Relmada Therapeutics in the second quarter valued at about $33,000. Institutional investors own 45.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RLMD shares. HC Wainwright began coverage on shares of Relmada Therapeutics in a research report on Thursday, June 18th. They issued a “buy” rating and a $12.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Relmada Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.00.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.